AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04242719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic stimulation
Description: Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.
Study NCT04242719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: About 20 ml of blood was drawn from the patient's antecubital vein and inserted into two 10-ml vacutainer tubes that contain trisodium citrate (T-LAB PRP Kit, T-Biyoteknoloji, Bursa, TURKEY). These tubes were placed in a refrigerated (+4 °C) centrifuge (Nüve NF 1200R, Nüve Laboratuar Teknolojileri, Ankara, TURKEY) and spun at 2500 rpm (580×g) for 8 min within 30 min of collection. Three different layers formed in the tubes: red blood cells at the bottom, platelet-rich plasma in the middle, and platelet-poor plasma in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe and immediately injected into the sub-tenon space of each eye after topical anesthesia with proparacaine hydrochloride (Alcaine, Alcon, USA) drops.
Study NCT01149226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chloral hydrate
Description: 30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
Study NCT01149226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chloral hydrate
Description: 30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
Study NCT03307967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT-PM
Description: SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
Study NCT00496652 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
Study NCT00496652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
Study NCT02915016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
Study NCT02915016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/MF59 vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
Study NCT02915016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/AS01B vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.
Study NCT02915016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
Study NCT02915016 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
Study NCT02717585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure Therapy (CPAP)
Description: Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
Study NCT02166905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given via intracutaneous injection
Study NCT02166905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO
Study NCT02166905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02166905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02166905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC
Study NCT03484091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyruan-One
Description: single dose intra-articular injection
Study NCT03484091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: single dose intra-articular injection
Study NCT03484091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: single dose intra-articular injection
Study NCT04262622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group TEA: thoracic epidural analgesia group
Description: in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter
Study NCT04262622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group RSB: rectus sheath block group
Description: Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
Study NCT06434259 — intervention group
Intervention type: DEVICE
Intervention: Digi-physical support system
Description: A support system named Evira will be used to provide behavioral treatment.
Study NCT01160978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80mg
Description: The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
Study NCT01160978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Rx
Description: The transplant recipients who have received an organ from non-treated donors.
Study NCT03220360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect pulp capping
Description: Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
Study NCT03220360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct pulp capping
Description: Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
Study NCT03220360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vital pulpotomy
Description: Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
Study NCT02044705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active and Healthy Families
Description: Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
Study NCT01670240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study NCT01670240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02975505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strict blood pressure control
Description: Systolic Blood Pressure Target \< 120 mm Hg (measured at home)
Study NCT03773692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive feedback and JITAI
Description: Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA.
Study NCT00418015 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood for OPRM1 analysis
Study NCT04377672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 Human Convalescent Plasma
Description: 1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL.
Study NCT03095716 — intervention group
Intervention type: OTHER
Intervention: laparoscopic surgery
Description: Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
Study NCT01509872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused Cognitive Behavioral Therapy
Description: 9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
Study NCT01509872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Friendly Space
Description: 9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
Study NCT01237028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
Study NCT02235402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine
Study NCT02235402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendrofluazide
Study NCT02235402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03686696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
Study NCT03686696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI
Description: Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
Study NCT03686696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB
Description: Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
Study NCT02856022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical ilioinguinal nerve stimulation
Description: Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1\~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks.
Study NCT02856022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Irrigation
Description: The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
Study NCT01586689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oxford House
Description: community-based recovery home for participants recovering from substance dependency
Study NCT01586689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Haven
Description: professionally-staffed treatment facility
Study NCT01586689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual aftercare
Description: control group - participants may or may not seek treatment on their own
Study NCT00652275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP
Description: 189 children will receive 3 doses of experimental vaccine
Study NCT00652275 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Verorab vaccine
Description: 189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
Study NCT03291132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: training camp
Description: The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months.
Study NCT05031143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease
Description: Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
Study NCT02622035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information
Description: Information about fruit and vegetable feeding for children framed in gain vs. loss manner
Study NCT02622035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion induction
Description: Film clip designed to induce anger or fear
Study NCT02622035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual perceptual load
Description: visual and interactivity-based load of virtual reality buffet environment
Study NCT01732536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S8 Sinus Implant
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Study NCT01732536 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: In-office bilateral sham procedure
Study NCT03150017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIRE
Description: Online pain management programme.
Study NCT02758223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCM allogeneic humane central memory T cells, cryopreserved
Description: Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
Study NCT00795964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized application of intraoperative tidal volume
Description: intraoperative mechanical ventilation with 6 ml/kg predicted body weight
Study NCT04092582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Description: MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
Study NCT04092582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
Study NCT00795964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized application of intraoperative tidal volume
Description: intraoperative mechanical ventilation with 12 ml/kg predicted body weight
Study NCT03585699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy Guided Spinal Biopsy
Description: Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis.
Study NCT02362984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
Study NCT02362984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
Study NCT00690274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF2.649
Description: up to 20mg per day
Study NCT00690274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to 20mg per day
Study NCT05638178 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, cohort study.
Study NCT00896246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klean-Prep®
Description: Four litres of solution administered orally as a divided dose.
Study NCT00896246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moviprep®
Description: Two litres of solution administered orally as a divided dose
Study NCT01244269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
Study NCT01732536 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
Study NCT01244269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 20mg three times daily for a total of 7 doses.
Study NCT01244269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10
Description: Blind gelatin capsule three times daily for a total of 7 doses.
Study NCT01244269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 20
Description: Blind gelatin capsule three times daily for a total of 7 doses